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Coeliac disease is a common small bowel enteropathy arising in genetically predisposed
individuals and caused by ingestion of gluten in the diet. Great advances have been
made in understanding the role of the adaptive immune system in response to gluten
peptides. Despite detailed knowledge of these adaptive immune mechanisms, the
complete series of pathogenic events responsible for development of the tissue lesion
remains less certain. This review contributes to the field by discussing additional
mechanisms whichmay also contribute to pathogenesis. These include the production of
cytokines such as interleukin-15 by intestinal epithelial cells and local antigen presenting
cells as a pivotal event in the disease process. A subset of unconventional T cells
called gamma/delta T cells are also persistently expanded in the coeliac disease (CD)
small intestinal epithelium and recent analysis has shown that these cells contribute
to pathogenic inflammation. Other unconventional T cell subsets may play a local
immunoregulatory role and require further study. It has also been suggested that, in
addition to activation of pathogenic T helper cells by gluten peptides, other peptides
may directly interact with the intestinal mucosa, further contributing to the disease
process. We also discuss how myofibroblasts, a major source of tissue transglutaminase
and metalloproteases, may play a key role in intestinal tissue remodeling. Contribution
of each of these factors to pathogenesis is discussed to enhance our view of this
complex disorder and to contribute to a wider understanding of chronic immune-
mediated disease.
Keywords: coeliac disease, pathogenesis, enteropathy, immunopathology, innate and adaptive immune response,
molecular mechanisms of disease
INTRODUCTION
Coeliac disease (CD) is a common inflammatory disorder of the small intestine resulting in
malabsorption. The seminal breakthrough was the discovery by Willem Dicke in 1950 that the
wheat protein gluten was the essential trigger causing the disease (1). In the following decades,
debate continued about the pathogenic mechanisms involved. Various theories were considered,
including the concept that gluten caused direct toxic damage to the intestine, that an enzyme
deficiency resulted in failure of gluten degradation or that gluten activated the immune system,
driving consequential gut damage (2).
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Gluten-induced activation of the adaptive immune response
has now been described in great detail and a central role for
immune system involvement is widely accepted. A key finding
supporting the role of the adaptive immune response was the
discovery that certain MHC class II molecules, in particular
HLA-DQ2, were a critical requirement for the development
of CD (3, 4). It was subsequently demonstrated that gluten-
derived peptides bound avidly to these MHC class II molecules,
enabling T helper (TH) cell activation (5, 6). The binding of these
peptides was markedly enhanced following their modification by
the enzyme tissue transglutaminase (TG2) (7). The role of TG2
was in part a serendipitous discovery, following the finding that
specific IgA antibodies found in CD were directed against this
enzyme (8).
Although initially considered a homogenous disorder, it is
now recognized that CD encompasses a wider clinical spectrum.
Patients can report a range of symptoms, some with clear
evidence of malabsorption and others virtually asymptomatic
(9, 10). Following treatment with a gluten-free diet, some
patients become acutely and rapidly sensitive to accidental gluten
exposure, whereas others may show little evidence of a reaction
(11–13). A pediatric presentation was the early classic form of CD
but it is now accepted that the condition can present at any age,
even into the seventh and eighth decades (14). A true increasing
incidence of CD is also reported, presumably reflecting a range
of yet to be identified environmental triggers of the condition
(15). The histological lesion can also vary considerably, with
some patients having only a minimal lymphocyte infiltration of
the gut epithelium (16), while others display profound changes,
so called villous atrophy (17, 18). The term “potential coeliac
disease” is also used for people with normal small intestinal
mucosa who are at increased risk of developing CD as indicated
by positive coeliac serology (10). Malignancy is the final outcome
in a subset of patients, but fortunately develops only in a minority
of subjects (9). The common type of malignancy associated
with CD, enteropathy-associated T cell lymphoma (EATL), is
lymphocytic in origin, reflecting the profound dysregulating
effects gluten has on the local immune system.
CD is sometimes considered to be an auto-immune disorder
and certain features support this contention, including a female
predisposition, HLA association, and comorbidity with many
classic autoimmune diseases, in particular thyroid disease (e.g.,
Grave’s disease, Hashimoto’s thyroiditis) and insulin dependent
diabetes mellitus (19). As in other auto-immune conditions,
a contribution by the intestinal microbiome is postulated
(20). However, if CD is caused by autoimmunity, one feature
makes this pathology unique: exclusion of an exogenous trigger
i.e., gluten from the diet, causes remission of symptoms and
mucosal damage. Nonetheless, some doubt continues as to
whether gluten exclusion fully restores a normal small intestinal
mucosa or whether consequences of the previous strong immune
activation remain. It has long been observed that chronic
immune activation by gluten in CD patients induces a permanent
change in the intra-epithelial lymphocyte (IEL) compartment,
characterized by an expanded and persistent presence of γ/δ IELs,
which was recently verified using cell sequencing methodology
(21–23). This observation suggests that even in apparently
healthy tissue, some subtle changes persist. However, such
findings are difficult to interpret given that many patients
ostensibly on a gluten-free diet continue to consume trace
amounts of gluten (24).
Irrespective of the above variables, a constant feature in
all patients is the MHC class II association, with virtually all
displaying a HLA-DQ2 or HLA-DQ8 genotype (25). As many as
39 other non-HLA loci have been found to associate with CD and
their potential contribution to disease heterogeneity has yet to be
determined. Remarkably, many non-coding regions are located
in these loci and their potential regulatory effects have just started
to be revealed (26). In addition, epigenetic factors may modulate
disease risk (27).
In addition to the well-established evidence of the adaptive
immune response to gluten, leading to damage to the intestine,
in this review we consider the possible involvement of other
immune components. Of note, it has been reported that
activation of the innate immune response may be a pre-
requisite for gluten stimulation of the adaptive response (28–
30). The α-gliadin peptide, p31-43, claimed to be responsible
for activation of this innate response, was also reported to cause
direct damage to the CD mucosa (28). Many studies report that
innate immune components such as neutrophils (31), eosinophils
(32–34), mast cells (35, 36) and complement proteins (37) are
activated in the disease process and potentially contribute to
disease pathogenesis. Consideration of this information may lead
to a more comprehensive understanding of CD pathology.
HOW DOES THE LESION DEVELOP IN CD?
Despite the series of seminal discoveries made concerning
activation of the adaptive immune system in CD, the precise
mechanisms responsible for development of the lesion remain
uncertain. Specifically, what events cause the tall small intestinal
villi to take on a flattened appearance in which villi are either
entirely absent or stubby in appearance? It is evident from both in
vivo and in vitro studies that enterocyte damage happens rapidly
following gluten exposure (38–43). Yet the question remains,
how does this lead to the eventual pathological features of the
lesion? Interestingly, although enterocytes are targeted in CD,
there is no evidence of tissue necrosis or ulceration, as is observed
in small intestinal Crohn’s disease (44). Although it is evident
that lymphocytes closely located to enterocytes display cytotoxic
properties (45, 46), is lymphocyte cytotoxicity the exclusive or
principal mechanism responsible for the tissue lesion in CD?
THE HISTOLOGICAL LESION IN CD
Biopsy of the small intestine is still the gold standard diagnostic
test in the investigation of CD. The lesion can display a
range of abnormalities and Marsh proposed a grading system,
subsequently modified by Oberhuber et al. (18), which is now
commonly used. TheMarsh I lesion is characterized by an almost
normal mucosa except for the infiltration of villi by IELs, the
Marsh II lesion by the additional presence of crypt hypertrophy,
and the Marsh III lesion by flattening of the mucosa caused
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by so-called villous atrophy and swelling of the lamina propria.
Although an increase in IELs is observed in all CD biopsies,
in some patients this increase may be limited to the tip of villi
(16, 47); even in the presence of this minimal lesion, some
display typical clinical features of CD including malabsorption.
Paradoxically, in other patients with a Marsh I lesion, there may
be no apparent evidence of malabsorption: these include patients
with dermatitis herpetiformis (48), first degree relatives of CD
patients and individuals with potential CD (10).
Although villous atrophy and infiltration of IELs are the major
reported features in coeliac mucosa, this is based on the limited
information provided by standard tissue staining and the two-
dimensional image observed with the light microscope. More
details can be provided by additional staining of further cell
populations and other structures. One feature of the remodeled
mucosa is alteration in the microvasculature and these immature
vascular structures may result in increased vessel permeability,
allowing cells and molecules access to the tissue (49). It has
been proposed that improved understanding of the true nature
of the CD lesion could be deduced by 3-D printing and
computerized modeling of the tissue (50). In recent times, robust
flow cytometry methodology and quantification of gamma/delta
(γδ) T cells have been proposed as complementary methods
for aiding CD diagnosis and monitoring, particularly helpful in
resolution of more difficult clinical cases (51, 52). Analysis of an
increase in γδ+ T cells with a decrease in CD3− IEL, the so-called
“coeliac lymphogram,” was also shown to be useful in diagnosing
seronegative CD cases (53). Such novel methods have proven
superior to traditional serological monitoring methods.
THE ENTEROCYTE—A TARGET CELL IN
CD?
Abnormalities in the morphology of enterocytes are usually
present in CD but are rarely commented on in routine histology
reports. These changes include a reduction in cell height with
the cell assuming a cuboidal instead of the normal columnar
shape and the migration of the nucleus from the typically basal
to a more apical position (54). Using a high content Cellomics
analysis system, we studied enterocyte morphology in detail and
confirmed a reduction in enterocyte height and noted shape
changes in the nucleus (55). Importantly, these changes were
found not only in patients with active CD but also in patients with
potential CD. Changes in the microvilli at the enterocyte apex
may also be noted, even when examined by light microscopy,
although these features are more clearly evident when studied by
electronmicroscopy (56). Microvilli are found to be either sparse,
absent or have irregular shapes.
These abnormal enterocyte features are presumably caused by
the inflammatory response in CD. The changes may preface cell
death, and indeed, increased small intestinal enterocyte apoptosis
has been demonstrated in CD in several studies (40, 57, 58).
Using TUNEL staining to detect fragmented DNA, Moss et al.
reported this finding in patients with untreated CD, and evidence
of apoptosis correlated with the level of enterocyte proliferation
(57). Maiuri et al. also described increased apoptosis in CD
tissue but these abnormalities appeared confined to tissue areas
displaying evidence of damage (40). Another study reported
increased expression of both FAS and FAS ligand death receptors
in the duodenal epithelium in untreated CD patients, together
with increased perforin expression and number of TUNEL
positive cells (59).
Raised circulating levels of intestinal fatty acid-binding
protein (I-FABP) in patients with active CD also provides
evidence of enterocyte damage (60–62). I-FABP is a low
molecular weight protein, specific to small intestinal epithelial
cells. Since I-FABP is highly expressed in the cytoplasm of these
cells, the circulating level of I-FABP is a very sensitive marker
for monitoring enterocyte damage and has been proposed as a
potential biomarker of disease activity in CD (63). Interestingly,
in patients with severe enteropathy, strong expression of I-
FABP is also noted in the crypts, and this may be linked to an
accelerated developmental program of enterocyte proliferation
and differentiation. As a consequence, while I-FABP is expressed
in fully differentiated enterocytes in homeostasis, it appears
earlier in crypt enterocytes when enteropathy is present (64).
A BROADER ROLE FOR INTESTINAL
EPITHELIAL CELLS?
Enterocytes are the predominant intestinal epithelial cell type
and together with other cells, including goblet cells, Paneth
cells and M cells, act as a first line of defense against potential
access from the gut of microorganisms and other noxious
agents (65, 66). However, intestinal epithelial cells have a wider
role in gut homeostasis, interacting on a constant basis with
commensal organisms and influencing the behavior of cells of
both the innate and adaptive immune system. Reactions with
microogranisms and danger signals is facilitated by the epithelial
surface expression of a range of innate receptors including toll
like receptors (67). Epithelial cells influence the behavior of
many intestinal cell populations including innate lymphoid cells
(ILC), neutrophils, basophils, macrophages, T cells and B cells
through the production and release of a range of cytokines
and chemokines including tumor necrosis factor alpha (TNF)-
α, interleukin (IL)-8, IL-18, IL-25, transforming growth factor
(TGF)-β and B cell activating factor (66, 68). Amongst its many
roles, a key function of intestinal epithelial cells is to allow
the orderly paracellular absorption of nutrients and ions and
to prevent access to potentially damaging substances including
dietary antigens. This led to the study of a series of tight junction
structures and the discovery of the protein zonulin, the only
known physiological modulator of intercellular tight junctions
(69). Increased release of zonulin is associated with gut barrier
dysfunction and gliadin peptides have been reported to trigger
this reaction (65).
A ROLE FOR DIRECT GLUTEN-INDUCED
ENTEROCYTE DAMAGE?
Details of enterocyte pathology following gluten exposure
have been investigated by both in vitro and in vivo challenge
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FIGURE 1 | Direct effect of peptic-tryptic digests of gliadin on intestinal enterocytes. Representative images of organ culture of healthy (n = 5) and coeliac (n = 5)
biopsies in the presence or absence of peptic-tryptic (PT) digests of gliadin demonstrates direct effects of gliadin. Treatment of coeliac biopsies for 24 h with PT gliadin
reveals significant changes in cytokeratin and tubulin staining, as demonstrated by fluorescence microscopy.
studies. In organ culture of biopsies taken from coeliac patients
co-cultured with gluten derived proteins, evidence of rapid
changes in enterocyte morphology has been reported. In several
studies, gluten caused reduction in enterocyte height (70–73)
and increased apoptosis of enterocytes (28, 41, 74, 75). We also
performed organ culture experiments employing a peptic/tryptic
digest of gluten and demonstrated derangement of several
enterocyte cytoskeletal proteins, including microfilaments,
intermediate filaments and microtubules; these changes were
evident after 4 h of culture but were even more marked after 24 h
(Figure 1) (76).
Several short-term in vivo challenge studies also reported
evidence of rapid enterocyte damage following infusion of gluten
fractions into the small intestine. When small intestinal biopsies
were taken at hourly intervals, significant histological damage
was observed after patients were given either gluten (77), gliadin
subfractions (38, 39) or the associated wheat protein glutenin
(78). The abnormalities included a reduction in enterocyte
height, an increase in IELs and a reduction in the villous/crypt
ratio. In some instances, these changes were noted as early as 2 h
after gluten exposure (78).
Taken together, these studies demonstrate rapid changes in
coeliac enterocyte morphology following gluten exposure. The
mechanisms responsible have yet to be identified. Although a
rapid response is more typical of innate immune involvement,
there is now evidence that a histological and cytokine response
to gluten and immunodominant gliadin peptides can take place
within hours. A study by Fraser et al. demonstrated that in vivo
challenge with residues 56–75 of α-gliadin resulted in reduction
of enterocyte height and an increase in IELs in biopsy tissue
within just 4 h (79). Moreover, it has been recently reported that
oral gluten challenge causes a significant elevation of plasma IL-2,
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suggestive of rapid activation of T lymphocytes, again within
4 h (80). The findings of these studies support a prominent role
for adaptive immunity in causing early tissue changes in the
CD lesion.
A ROLE FOR ENTEROCYTE
PROLIFERATION?
It has been suggested that hyperproliferation of enterocytes is
the principal pathological event responsible for apparent villous
atrophy in CD mucosa, rather than direct destruction of the
villous structure (50, 81, 82). Marsh and Heal in particular have
argued this point and state that the term “villous atrophy” is
a misnomer (50). They postulate that the overgrowth of the
crypt cell population surrounds and dwarfs the villous structure
and cause its shrunken appearance. Crypt cell proliferation was
investigated by Wright et al. and an up to 6-fold increase in crypt
cell production was calculated with an associated increase in the
mitotic index (83).
The increased crypt cell proliferation may due to the
reparative process to replace damaged enterocytes shed into
the intestinal lumen. However, it has also been reported that
proliferation may be due to a direct effect of gliadin peptides
on the coeliac mucosa (84). In cultured coeliac duodenal biopsy
tissue the p31-43 gliadin peptide was shown to increase crypt
cell proliferation, apparently via the epidermal growth factor
pathway (85). This effect was mediated by enhancing epithelial
growth factor receptor signaling in a mechanism involving
altered vesicular trafficking (84, 86). It was also postulated that
this proliferative effect was further augmented by increased IL-15
production, stimulated by the gliadin peptide (29).
A ROLE FOR GLIADIN PEPTIDES IN
CAUSING AN INNATE RESPONSE?
In addition to its reported effect on crypt cell proliferation (84),
many additional studies have focused on the α-gliadin peptide,
p31-43 and its potential to cause direct activation of the innate
immune system. Within 20min of exposure to this peptide
evidence of enterocyte actin reorganization was reported in organ
culture experiments (87). Further study has revealed various
additional pathogenic effects. p31-43 was shown to inhibit the
subunit of the chloride channel (CFTR) and thereby cause NF-kB
activation, induction of IL-15 and TG2 activation, with a range
of inflammatory consequences (88). Moreover, p31-43 is able to
self-assemble in oligomers with potential important effects (89).
In vivo analysis in a murine model showed that activation of the
NLRP3 inflammasome, either by direct detection of oligomers or
indirectly by sensing danger signals, is required for histological
changes in the small intestinal mucosa (90). Finally, the peptide
was shown to induce a type I interferon (IFN) response in
mice (91). Of note, high levels of IFNα can be observed in the
duodenal mucosa from coeliac patients (84) and this cytokine
has been suggested to promote T helper (TH) type 1 responses
in CD (92).
More recently, various studies were conducted to evaluate the
role of a particular enteric virus which causes the induction of
proinflammatory signals that may promote breakdown of oral
tolerance to gluten (93). Commensal microbiota also has a role to
play in the induction of local inflammation. Elastase-producing
Pseudomonas aeruginosa isolated from the duodenal biopsies of
CD patients was able to degrade a gluten-derived 33-mer peptide,
producing shorter fragments which cross themucosal barrier and
display increased immunogenicity (94). Therefore, viral infection
and the activity of P. aeruginosa, as examples of members of
the microbiota which can elicit proinflammatory signals on
intestinal cells which drive or amplify villous damage. Other
mechanisms, apart from conventional immunogenic peptides,
that may play a role are the amylase trypsin inhibitors present
in wheat. These proteins are resistant to intestinal digestion, can
directly activate Toll-like receptor 4 (TLR4) and may support
intestinal T cell activation in celiac disease (95). However, the
main immunogenic peptide, responsible for stimulating the
adaptive immune response is a 33-mer gliadin peptide, p56-88,
which contains several overlapping sequences that bind with
high affinity to susceptibility HLA molecules (92). A further
small eight residue gliadin peptide is reported to act through
the stimulation of particular dendritic cells, can amplify the
inflammatory response (96).
A ROLE FOR CONVENTIONAL AND
UNCONVENTIONAL LYMPHOCYTES?
T lymphocytes and B cell derived plasma cells are markedly
increased in the coeliac lesion. In the untreated coeliac mucosa,
plasma cells secreting IgA are increased 2.4-fold and represent
some 66% of antibody secreting cells (97). Increases in IgM and
IgG secreting cells also are found, with these cells accounting for
some 28 and 6% of plasma cells in the lesion. Antibodies of all
three isotypes to gliadin and auto-antigen targets can be detected
not only in intestinal secretions but also in the circulation. Assays
for these antibodies are of immense value in the diagnosis and
monitoring of disease activity in CD patients. In addition, gut-
resident plasma cells presenting the immunodominant gluten
peptide DQ2.5-glia-α1a have been shown to be abundant in the
CD lesion, suggesting an important local antigen presentation
role (98). These cells also act as a source of cytokines, including
the chemokine CXCL10 (99).
Gluten-reactive T lymphocytes are found in the lamina
propria and are comprised of α/β T cell receptor positive cells
bearing a CD4 co-receptor, identifying them as TH cells (3, 100).
However, cloning studies have revealed that only 0.5–1.8% of
CD gut-derived CD4T cells are truly gluten reactive (101).
These gluten-reactive cells display a TH1 phenotype in response
to gluten peptides, with cytokine production predominated
by IFNγ (102). Gliadin-specific TH17 cells have also been
described, which co-produce IL-17 and IFNγ (103). Gluten
reactive CD8+ T cells have also been described in the lamina
propria following challenge with the pA2 gliadin peptide (41).
Nonetheless, studies in mice and humans have shown that the
presence of these gluten-reactive T cells alone is not sufficient
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to drive pathological changes to the villous architecture (104–
106). Thus, in potential CD, where individuals demonstrate
an adaptive immune response to gluten, characterized by the
presence of serum endomysial antibodies, no histological lesion
is present. This suggests that additional factors may be required
to drive tissue damage (107).
Parallels have been drawn between the progression of
CD and graft vs. host disease, suggesting a key role for T
cells in disease pathogenesis (108). In addition to gluten-
reactive CD4+ α/β T cells, a role for CD8+ α/β IELs in
enterocyte destruction has also been shown, whereby these cells
acquire an aberrant natural killer (NK)-like phenotype and kill
enterocytes in a T cell receptor (TCR)-independent manner.
These mechanisms, driven by IL-15 (46, 68), are summarized in
Figure 2. This NK-like action is characterized by strong IFNγ
production, upregulation of activating NK receptors NKG2D and
CD94/NKG2C (46), concurrent downregulation of inhibitory co-
receptors CD94/NKG2A (106) and cytotoxic ability. Engagement
of activating NK receptors by stress molecules expressed on
enterocytes triggers the cytolytic function of these CD8+ IELs.
In patients with CD, enterocytes upregulate expression of stress
molecules such as heat shock proteins (HSP), MHC class I
polypeptide-related sequence A (MICA), HLA-E and IL-15 (45,
109, 110). However, gluten-reactive CD4+ T cells have been
shown to be required to fully license the cytolytic NK activity
of these CD8+ IELs (106, 111, 112). A recent mouse model
of CD has also demonstrated the key role of CD4+ T cells
and HLA-DQ8 in mediating cytotoxic lymphocyte (CTL)-driven
villous destruction (111). Depletion of either CD4+ or CD8+
T cell populations prevented villous damage in these transgenic
HLA-DQ8+ mice overexpressing IL-15. CD4+ T cell depletion
resulted in a failure of CD8+ CTLs to upregulate RAE-1, the
murine ligand for NKG2D, providing further evidence that the
NKG2D pathway is important in CD4-mediated CTL licensing.
Upregulation of QA-1, the mouse ligand for NKG2 receptors
paired with CD94, was unaffected by CD4 depletion, showing
that this mechanism is specific to NKG2D. This study also
revealed critical roles for gluten, IL-15, HLA-DQ8, TG2, and
CD4T cells, working in concert to promote IFNγ responses and
expansion of activated cytolytic CD8 IELs which mediate villous
atrophy. IFNγ, a prominent cytokine in CD pathogenesis, is
produced not only by gluten-reactive lamina propria TH cells
but also by populations of IELs, including γ/δ IELs (113). In
addition to IL-15, cytokines IL-2 and IL-21 are two further
important cytokine products of gluten reactive TH cells and
contribute to the adaptive immune pathogenesis of CD (80, 114–
116), however, of interest they were not shown to be critical for
development of villous damage in this recent mouse model (107).
A study on human tissue reports that the majority of CD patients
overexpress both IL-15 and IL-21 and in vitro analysis showed
these cytokines synergise to activate CTL IEL populations and
thus drive villous damage, in a cooperative and non-redundant
manner (117).
Intriguingly, individuals with potential CD do not
demonstrate an increase in activating NK receptors nor IL-15 or
IL-21, suggesting that additional factors may also be required to
drive the full NK-like phenotype. Potential candidates include
gut microbial components (118) or viral infection (119, 120).
This is further supported by a recent study in which ubiquitous
bacterial peptides were shown to activate gliadin reactive T cells,
suggesting the possibility that common bacterial antigens could
act as trigger stimuli in the development of CD (121).
Whereas, CD4+ T cells predominate in the lamina propria, the
human small intestinal epithelium is predominantly populated
by CD8+ α/β IELs, γ/δ IELs, and a smaller proportion of
lymphocytes which do not express a T cell receptor, and therefore
are classed as innate lymphocytes (21, 122). This latter population
includes NK cells and ILCs. The CD8+ α/β IELs group also
includes mucosal-associated invariant T (MAIT) cells and, albeit
at low levels, invariant NK T (iNKT) cells (23). It is assumed that
most of these cell types play a lesser but similar destructive role
to their conventional T cell counterparts, since unconventional
T cells constitutively express NK markers, display an effector
memory phenotype, and are capable of rapid and potent cytolytic
responses. Indeed, ILCs have been shown to be capable of killing
enterocytes via the NK receptor DNAM1 (123).
The role of discrete IEL subsets warrants further study,
particularly in light of the long-held observation that γ/δ IELs
remain elevated in the coeliac gut long after removal of gluten
from the diet and resolution of intestinal damage (23, 124). In
contrast to the deleterious role proposed for CD8+ α/β IELs
in CD, it is hypothesized that γ/δ IELs play a more regulatory
role in the gut (125, 126). We and others have described an
abundance of Vδ1 type γ/δ T cells in the CD epithelium, in
both pediatric and adult CD (23, 127–130). This subset is known
to possess potent cytolytic and regulatory functions in humans
(131). Like their mouse counterparts, human γ/δ IELs in skin
can secrete growth factors, specifically insulin-like growth factor,
and play an important role in tissue repair (132). Whether this
active role in tissue repair also occurs in the gut is unclear, but
human NKG2A+ CD8+ γ/δ IELs have been shown to effectively
dampen the proinflammatory and cytotoxic action of their α/β
IELs counterparts via production of the immunosuppressive
cytokine TGF-β (133). TGF-β is an immunosuppressive cytokine
which exerts many anti-inflammatory effects, including driving
differentiation of regulatory T cells and TH17 cell populations,
which then produce more TGF-β in an autocrine manner (134).
This suggests that lymphocyte-mediated damage to the coeliac
small intestine may require dysregulation of both α/β and γ/δ IEL
subtypes. In this scenario, a two-step process would be required
tomediate gut damage—CD8+ α/β IELs acquire an aberrant NK-
like cytotoxic phenotype coupled with γ/δ IELs losing regulatory
function. This raises an intriguing possibility that maintenance
of γ/δ T cell regulatory function could explain the phenotype of
potential CD, a scenario where γ/δ IELs keep α/β IEL cytotoxicity
in check. Indeed, recent studies detailing long-term genomic
and functional changes in the composition of the γ/δ IEL
compartment in CD has shown that a subset of Vγ4+/Vδ1+ type
γ/δ IELs, which have a role in tissue healing and homeostasis,
is lost and replaced by a persistent IFNγ producing Vδ1+ T
cell population, thereby supporting this hypothesis (21, 22). The
role of other lymphocyte subsets such as MAIT cells, iNKT cells
and NK cells in CD is less well-understood (23). NK cells in
particular appear to be capable of both deleterious and protective
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FIGURE 2 | Mechanisms of pathogenesis in coeliac disease. (A) It is well established that peptides derived from gluten are modified by TG2 and presented by antigen
presenting cells in mesenteric lymph nodes (MLN) to CD4+ T cells in the context of HLA-DQ2. The resulting TH1 type response results in IFNγ production and
intestinal inflammation. Chronic inflammation leads to expansion and persistence of Vδ1+γδ T cells, which also contribute to IFNγ production. Gluten peptides induce
expression of IL-15 and stress molecules on enterocytes. The increased levels of IL-15 promote a NK-like phenotype in CD8+ T cells, contributing directly to
enterocyte death. A proportion of CD8+γδ+ T cells are thought to play a regulatory role through secretion of TGF-β. Plasma cells are also abundant in the lesion where
many express the immunodominant gluten peptide DQ2.5-glia-α1a and are induced to secrete antibodies that bind to TG2 and other targets. (B) Other less
well-characterized mechanisms may play a role in lesion development. Intestinal myofibroblasts contribute to tissue remodeling by the secretion of matrix
metalloproteases (MMPs) and via their contractile properties. These cells strongly express TG2 and α-actin. Innate-like lymphocytes including natural killer (NK cells),
innate lymphoid cells (ILC), invariant natural killer T cells (iNKT) and mucosal-associated invariant T (MAIT) cells may all contribute to the lesion. Granulocytes, including
eosinophils, neutrophils and basophils, and also mast cells have been detected in higher levels and may be involved in disease pathogenesis.
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effects on the intestine and are also susceptible to functional and
metabolic inhibition by TGF-β (135); thus, their contribution to
CD pathogenesis requires further elucidation (136).
A ROLE FOR INNATE IMMUNE CELLS IN
THE INTESTINAL LESION?
In addition to the increased number of T cells and plasma cells
in patients with active CD, several studies describe increased
populations of cells of the innate immune response, including
eosinophils (32–34), basophils (50), mast cells (32, 35, 36),
neutrophils (137, 138) and dendritic cells (139, 140). The
potential contribution of both eosinophils and mast cells is
supported by experiments involving gliadin challenge to an
isolated segment of jejunum: this caused a four-fold increase
in eosinophil granule specific protein secretion and a two-fold
increase of histamine secretion, with maximum levels found
within 1 h (141). A prominent extracellular deposit of eosinophil
granule specific protein in the lamina propria of the atrophic
intestinal mucosa was also found (31). Furthermore, eosinophils
were noted to be in an activated state in CD and Brandtzaeg
postulated that IgA might play a role in both eosinophil
recruitment and activation (97). Mast cell numbers are also
increased in active CD, and found to correlate with the Marsh
histological score and become cellular sources of TNFα, IL-6, IL-
17 and monocyte chemoattractant protein 1 (36, 50). These data
indicate that eosinophils and mast cells may both be involved in
early gliadin-induced reactions in the small intestine and could
contribute to the celiac lesion.
Neutrophils may also play a role in the coeliac lesion; in
the early phase of gluten challenge, increased numbers of these
cells have been observed with a 20-fold increase calculated (137,
138). The rapid production of the chemokine IL-8 by gluten
activated T cells helps explain this neutrophil migration (80). In
isolated jejunal segment experiments, gluten exposure caused a
5-fold increase in prostaglandin E2 (142) and a 3.5-fold increase
in myeloperoxidase in the perfusion fluid (31). Furthermore,
using gene expression profiling, chronic recruitment of activated
neutrophils to CD biopsy tissue was discovered, even in patients
in remission (143). In another study, after a 3-day gluten
challenge, an increase in density of neutrophils as well as a rapid
accumulation of monocyte/dendritic cells was observed (140).
Of interest, in a murine study, gliadin peptides were found to
have neutrophil chemoattractant properties (144). Dendritic cells
are the critical players in innate immunity as well as adaptive
response. Distinct subsets may display different functions, as
induction of strong inflammatory response, driving the gluten-
specific T cell response and control the immune response by
inducing regulatory T cells (139, 145).
A ROLE FOR ANTI-TG2 ANTIBODIES IN CD
PATHOGENESIS?
Detection of anti-TG2 autoantibodies is an exceptionally specific
and sensitive tool used for CD diagnosis. The most commonly
accepted model for the development of this autoantibody
response is the hapten-carrier complex mechanism, as proposed
by Sollid et al. (146). The hypothesis suggests that TG2-gliadin
complexes are presented by TG2-specific B cells to gliadin-
specific T cells and receive help for antibody production.
While this model does not necessitate TG2-reactive T cells,
separate studies by Comerford et al. and Ciccocioppo et al.
demonstrate that these autoreactive T cells can be detected in
patients (147, 148).
Whether or not autoantibodies play a role in the development
of the lesion remains unclear. The fact that IgA deficiency
does not preclude the development of CD suggests that
IgA isotype autoantibodies are not essential for disease
development. However, in the related gluten-sensitive condition
dermatitis herpetiformis, it appears that autoantibodies against
transglutaminase 3 (another member of the TG family) do
appear to play a role in pathogenesis as demonstrated by the
presence of IgA deposits at sites of neutrophil infiltration in
the skin (149). Unlike CD, dermatitis herpetiformis is not
observed in patients that are IgA deficient (150). It has been
proposed that anti-TG2 autoantibodies influence the disease
process in CD by having a direct effect upon enterocytes.
Purified anti-TG2 antibodies have been shown to inhibit crypt
cell differentiation (151), interfere with proliferation by binding
membrane TG2 (85), and enhance gliadin trafficking across
the gut epithelium (152). It has also been suggested that
anti-TG2 could interfere with enterocyte differentiation by
blocking TGF-β activation, a cytokine that plays an important
role in this process (151). Other effects have been reported
including inhibition of angiogenesis, and increases in vascular
permeability (153).
A ROLE FOR COMPLEMENT?
Few studies have examined the possibility of complement
involvement in CD pathogenesis. In early reports, C3 deposits
and proteins of the terminal complement pathway were shown
in the small intestine, concentrated sub-epithelially and in the
lamina propria (37). Untreated CD patients typically have high
levels of IgG1 and IgG3 anti-gliadin antibodies in their serum
(154) both of which are capable of activating complement (155).
Sub-epithelial IgA-TG2 deposits, found in the early stages of CD
(156) might also play a role, and polymeric IgA has been shown
to activate complement via the MBL pathway (157). Activation
of the classical complement pathway would result in increased
production of C3a and C5a, both capable of contributing to the
coeliac lesion by increasing vascular permeability and causing
mast cell degranulation. In addition, C5a as a chemotactic factor
could increase the migration of eosinophils, neutrophils and
monocytes to the lesion and initiate release of products such
as prostaglandins (142). Complement activation could therefore
explain the rapid onset of gluten induced symptoms observed in
some patients with CD (11, 12).
A ROLE FOR INTESTINAL
MYOFIBROBLASTS?
Intestinal subepithelial myofibroblasts possess a broad range
of biological functions and are likely to play a central role
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FIGURE 3 | Myofibroblasts strongly co-express TG2 and α-actin in coeliac disease. Dual color confocal microscopy demonstrates that intestinal myofibroblasts stain
positive for α-actin (green) in healthy control tissue (n = 5) (a). In active coeliac disease (n = 11) (b) these cells upregulate TG2 (red) and significant co-expression is
apparent (yellow) (Cooper et al., manuscript in preparation). Original magnification x40.
in architectural remodeling in CD. Myofibroblasts synthesize
many components required for the extracellular matrix and
the basement membrane and also control the degradation of
these structures through the release of matrix metalloproteases
(MMPs) along with inhibitors of these enzymes, the tissue
inhibitors of metalloproteases (TIMPs) (158). Several studies
have described increased mRNA and protein levels of MMP-
1, MMP-3, MMP-9, MMP-12, and TIMP-1 in the coeliac
lesion (159–161). In some instances, levels of MMPs correlated
with the degree of histological damage. Several cytokines are
critical to the function of myofibroblasts, including TGF-
β (162). In inflammatory bowel disease the production of
MMPs by myofibroblasts in is thought to be driven by IL-
1β and TNF-α (163), and the latter cytokine is produced by
IEL in CD (164). IFNγ and IL-21 are additional candidate
cytokines which may stimulate MMP production in the coeliac
lesion (159, 165).
In assembling the structure of the small intestine, TG2
plays a central role and myofibroblasts have been shown
to strongly express TG2 in active CD (166). Using confocal
microscopy, we have confirmed this finding and demonstrated
that TG2 expression strongly co-localizes with increased
smooth muscle α-actin expressed by these cells in active
disease (manuscript in preparation) (Figure 3). In an in
vitro model, it was found that IgA autoantibodies to TG2
interfere with the effect of TGF-β on myofibroblasts; this
resulted in the increased proliferation of enterocytes (151).
Finally, myofibroblasts also interact with the immune
system, express MHC class II as well as CD80 and CD86,
and have been shown to act as non-professional antigen
presenting cells (167). It has also been demonstrated that
myofibroblasts induce the proliferation and differentiation
of regulatory T cells (168) suggesting a possible role in
immune homeostasis.
Taken together, these findings suggest that intestinal
myofibroblasts could play an important tissue remodeling role
in the coeliac lesion as well as being a potential venue for
epitope spreading. The potential contribution of myofibroblasts
with multiple cellular and other immune components to CD
pathogenesis is represented in Figure 2B.
CONCLUSION
Features of CD suggest that it can be considered an autoimmune
disease with gluten as an environmental trigger causing
activation of a highly specific adaptive immune response. An
increase in IELs is a classic finding in CD and some conventional
lymphocytes with a NK-like phenotype contribute to enterocyte
destruction. The function of other IEL populations, such as
γ/δ IELs, in CD is less certain and work to date suggests
these cells may play an important local immune regulatory
role. Intestinal epithelial cells, through their production of IL-
15, play a dynamic role in disease pathogenesis in addition to
being targets of the immune response. There is also evidence
that cells of the innate immune system, including eosinophils,
mast cells and neutrophils, contribute to disease pathogenesis.
A further cell population, myofibroblasts, are an important
source of TG2 and metalloproteases and therefore may also play
a central pathogenic role in CD. Controversy surrounds the
issue of whether non-immune gliadin peptides contribute to the
disease process. Some studies report that one such peptide, p31-
43, can cause direct damage to enterocytes and also stimulate
enterocyte proliferation. The failure to identify a receptor for
this peptide has been used to reject its involvement in the
disease process. If alternate gluten peptides cause innate cell
activation, this will be important in designing future gluten
avoidance strategies.
Frontiers in Immunology | www.frontiersin.org 9 July 2020 | Volume 11 | Article 1374
Dunne et al. Tissue Damage in Coeliac Disease
AUTHOR CONTRIBUTIONS
All authors contributed to the planning, writing and
editing of this manuscript, and approve this submitted
version for publication. MD and GB contributed equally to
creating the manuscript. Figures were constructed by GB
and MD.
ACKNOWLEDGMENTS
We thank Dr. Sarah Cooper and Dr. Jean Dunne for their work
on the confocal imaging of intestinal myofibroblasts in the coeliac
lesion. We would also like to express our gratitude to Sharon
Wilson for her organ culture work concerning the effects of
gliadin on enterocyte cytoskeletal proteins.
REFERENCES
1. Van De Kamer JH, Weijers HA, Dicke WK. Coeliac disease. IV. An
investigation into the injurious constituents of wheat in connection with
their action on patients with coeliac disease. Acta Paediatr. (1953) 42:223–
31. doi: 10.1111/j.1651-2227.1953.tb05586.x
2. Auricchio S, De Ritis G, De Vincenzi M, Silano V. Toxicity
mechanisms of wheat and other cereals in celiac disease and
related enteropathies. J Pediatr Gastroenterol Nutr. (1985)
4:923–30. doi: 10.1097/00005176-198512000-00012
3. Lundin KE, Scott H, Hansen T, Paulsen G, Halstensen TS, Fausa O, et al.
Gliadin-specific, HLA-DQ (alpha 1∗0501,beta 1∗0201) restricted T cells
isolated from the small intestinal mucosa of celiac disease patients. J Exp
Med. (1993) 178:187–96. doi: 10.1084/jem.178.1.187
4. Lundin KE, Sollid LM, Qvigstad E, Markussen G, Gjertsen HA, Ek J, et al. T
lymphocyte recognition of a celiac disease-associated cis- or trans-encoded
HLA-DQ alpha/beta-heterodimer. J Immunol. (1990) 145:136–9.
5. Gjertsen HA, Lundin KE, Sollid LM, Eriksen JA, Thorsby E. T cells
recognize a peptide derived from alpha-gliadin presented by the celiac
disease-associated HLA-DQ (alpha 1∗0501, beta 1∗0201) heterodimer. Hum
Immunol. (1994) 39:243–52. doi: 10.1016/0198-8859(94)90267-4
6. van de Wal Y, Kooy YM, Drijfhout JW, Amons R, Koning F.
Peptide binding characteristics of the coeliac disease-associated DQ
(alpha1∗0501, beta1∗0201) molecule. Immunogenetics. (1996) 44:246–
53. doi: 10.1007/s002510050120
7. Vader LW, de RuA, van derWal Y, Kooy YMC, BenckhuijsenW,MearinML,
et al. Specificity of tissue transglutaminase explains cereal toxicity in celiac
disease. J Exp Med. (2002) 195:643–9. doi: 10.1084/jem.20012028
8. Dieterich W, Ehnis T, Bauer M, Donner P, Volta U, Riecken EO, et al.
Identification of tissue transglutaminase as the autoantigen of celiac disease.
Nat Med. (1997) 3:797–801. doi: 10.1038/nm0797-797
9. Lebwohl B, Sanders DS, Green PHR. Coeliac disease. Lancet. (2018) 391:70–
81. doi: 10.1016/S0140-6736(17)31796-8
10. Ludvigsson JF, Leffler DA, Bai JC, Biagi F, Fasano A, Green PHR, et al.
The Oslo definitions for coeliac disease and related terms. Gut. (2013)
62:43–52. doi: 10.1136/gutjnl-2011-301346
11. Bruins MJ. The clinical response to gluten challenge: a review of the
literature. Nutrients. (2013) 5:4614–41. doi: 10.3390/nu5114614
12. Laurin P, Wolving M, Fälth-Magnusson K. Even small amounts of gluten
cause relapse in children with celiac disease. J Pediatr Gastroenterol Nutr.
(2002) 34:26–30. doi: 10.1097/00005176-200201000-00007
13. Barratt SM, Leeds JS, Sanders DS. Factors influencing the type, timing
and severity of symptomatic responses to dietary gluten in patients with
biopsy-proven coeliac disease. J Gastrointestin Liver Dis. (2013) 22:391–6.
14. Collin P, Vilppula A, Luostarinen L, Holmes GKT, Kaukinen K. Review
article: coeliac disease in later life must not be missed. Aliment Pharmacol
Ther. (2018) 47:563–72. doi: 10.1111/apt.14490
15. Ludvigsson JF, Rubio-Tapia A, van Dyke CT, Melton LJ, Zinsmeister AR,
Lahr BD, et al. Increasing incidence of celiac disease in a north American
population. Am J Gastroenterol. (2013) 108:818–24. doi: 10.1038/ajg.2013.60
16. Järvinen TT, Collin P, Rasmussen M, Kyrönpalo S, Mäki M,
Partanen J, et al. Villous tip intraepithelial lymphocytes as markers
of early-stage coeliac disease. Scand J Gastroenterol. (2004)
39:428–33. doi: 10.1080/00365520310008773
17. Marsh MN. Gluten, major histocompatibility complex, and the small
intestine. A molecular and immunobiologic approach to the spectrum
of gluten sensitivity (’celiac sprue’). Gastroenterology. (1992) 102:330–
54. doi: 10.1016/0016-5085(92)91819-P
18. Oberhuber G, Granditsch G, Vogelsang H. The histopathology
of coeliac disease: time for a standardized report scheme for
pathologists. Eur J Gastroenterol Hepatol. (1999) 11:1185–
94. doi: 10.1097/00042737-199910000-00019
19. Lundin KEA, Wijmenga C. Coeliac disease and autoimmune disease -
genetic overlap and screening. Nat Rev Gastroenterol Hepatol. (2015) 12:507–
15. doi: 10.1038/nrgastro.2015.136
20. Krishnareddy S. The microbiome in celiac disease. Gastroenterol Clin North
Am. (2019) 48:115–126. doi: 10.1016/j.gtc.2018.09.008
21. Mayassi T, Ladell K, Gudjonson H, McLaren JE, Shaw DG, Tran MT, et al.
Chronic inflammation permanently reshapes tissue-resident immunity in
celiac disease. Cell. (2019) 176:967–81.e19. doi: 10.1016/j.cell.2018.12.039
22. Eggesbø LM, Risnes LF, Neumann RS, Lundin KEA, Christophersen A, Sollid
LM. Single-cell TCR sequencing of gut intraepithelial γδ T cells reveals
a vast and diverse repertoire in celiac disease. Mucosal Immunol. (2019)
13:313–21. doi: 10.1038/s41385-019-0222-9
23. Dunne MR, Elliott L, Hussey S, Mahmud N, Kelly J, Doherty DGDG,
et al. Persistent changes in circulating and intestinal γδ T cell subsets,
invariant natural killer T cells and mucosal-associated invariant T
cells in children and adults with coeliac disease. PLoS ONE. (2013)
8:e76008. doi: 10.1371/journal.pone.0076008
24. Syage JA, Kelly CP, Dickason MA, Ramirez AC, Leon F, Dominguez R, et al.
Determination of gluten consumption in celiac disease patients on a gluten-
free diet. Am J Clin Nutr. (2018) 107:201–207. doi: 10.1093/ajcn/nqx049
25. Koning F. Pathophysiology of celiac disease. TL - 59 Suppl
1. J Pediatr Gastroenterol Nutr. (2014) 59 (Suppl 1) :S1–
4. doi: 10.1097/01.mpg.0000450391.46027.48
26. Olazagoitia-Garmendia A, Santin I, Castellanos-Rubio A.
Functional implication of celiac disease associated lncRNAs
in disease pathogenesis. Comput Biol Med. (2018) 102:369–
75. doi: 10.1016/j.compbiomed.2018.08.013
27. Dieli-Crimi R, Cénit MC, Núñez C. The genetics of celiac disease: a
comprehensive review of clinical implications. J Autoimmun. (2015) 64:26–
41. doi: 10.1016/j.jaut.2015.07.003
28. Maiuri L, Ciacci C, Ricciardelli I, Vacca L, Raia V, Auricchio
S, et al. Association between innate response to gliadin and
activation of pathogenic T cells in coeliac disease. Lancet. (2003)
362:30–7. doi: 10.1016/S0140-6736(03)13803-2
29. Barone MV, Troncone R, Auricchio S. Gliadin peptides as triggers of the
proliferative and stress/innate immune response of the celiac small intestinal
mucosa. Int J Mol Sci. (2014) 15:20518–37. doi: 10.3390/ijms151120518
30. Kim SM, Mayassi T, Jabri B. Innate immunity: actuating the gears of celiac
disease pathogenesis. Best Pract Res Clin Gastroenterol. (2015) 29:425–
35. doi: 10.1016/j.bpg.2015.05.001
31. Hällgren R, Colombel JF, Dahl R, Fredens K, Kruse A, Jacobsen NO, et al.
Neutrophil and eosinophil involvement of the small bowel in patients
with celiac disease and crohn’s disease: studies on the secretion rate and
immunohistochemical localization of granulocyte granule constituents. Am
J Med. (1989) 86:56–64. doi: 10.1016/0002-9343(89)90230-1
32. Marsh MN, Hinde J. Inflammatory component of celiac sprue mucosa.
I. Mast cells, basophils, and eosinophils. Gastroenterology. (1985) 89:92–
101. doi: 10.1016/0016-5085(85)90749-8
33. Desreumaux P, Janin A, Colombel JF, Prin L, Plumas J, Emilie D, et al.
Interleukin 5 messenger RNA expression by eosinophils in the intestinal
Frontiers in Immunology | www.frontiersin.org 10 July 2020 | Volume 11 | Article 1374
Dunne et al. Tissue Damage in Coeliac Disease
mucosa of patients with coeliac disease. J Exp Med. (1992) 175:293–
6. doi: 10.1084/jem.175.1.293
34. Colombel JF, Torpier G, Janin A, Klein O, Cortot A, Capron M. Activated
eosinophils in adult coeliac disease: Evidence for a local release of major basic
protein. Gut. (1992) 33:1190–1194. doi: 10.1136/gut.33.9.1190
35. Strobel S, Busuttil A, Ferguson A. Human intestinal mucosal mast cells:
expanded population in untreated coeliac disease. Gut. (1983) 24:222–
7. doi: 10.1136/gut.24.3.222
36. Frossi B, Tripodo C, Guarnotta C, Carroccio A, De Carli M,
De Carli S, et al. Mast cells are associated with the onset and
progression of celiac disease. J Allergy Clin Immunol. (2017)
139:1266–274.e1. doi: 10.1016/j.jaci.2016.08.011
37. Halstensen TS, Hvatum M, Scott H, Fausa O, Brandtzaeg P. Association
of subepithelial deposition of activated complement and immunoglobulin
G and M response to gluten in celiac disease. Gastroenterology. (1992)
102:751–9. doi: 10.1016/0016-5085(92)90155-R
38. Ciclitira PJ, Evans DJ, Fagg NL, Lennox ES, Dowling RH. Clinical
testing of gliadin fractions in coeliac patients. Clin Sci. (1984) 66:357–
64. doi: 10.1042/cs0660357
39. Sturgess R, Day P, Ellis HJ, Lundin KE, Gjertsen HA, Kontakou M,
et al. Wheat peptide challenge in coeliac disease. Lancet. (1994) 343:758–
61. doi: 10.1016/S0140-6736(94)91837-6
40. Maiuri L, Ciacci C, Raia V, Vacca L, Ricciardelli I, Raimondi F, et al. FAS
engagement drives apoptosis of enterocytes of coeliac patients. Gut. (2001)
48:418–24. doi: 10.1136/gut.48.3.418
41. Mazzarella G, Stefanile R, Camarca A, Giliberti P, Cosentini E, Marano C,
et al. Gliadin activates HLA class I-restricted CD8+ T cells in celiac disease
intestinal mucosa and induces the enterocyte apoptosis. Gastroenterology.
(2008) 134:1017–27. doi: 10.1053/j.gastro.2008.01.008
42. Londei M, Ciacci C, Ricciardelli I, Vacca L, Quaratino S, Maiuri L. Gliadin
as a stimulator of innate responses in celiac disease. Mol Immunol. (2005)
42:913–8. doi: 10.1016/j.molimm.2004.12.005
43. Maiuri L, Picarelli A, BoirivantM, Coletta S,Mazzilli M, DeVincenziM, et al.
Definition of the initial immunologic modifications upon in vitro gliadin
challenge in the small intestine of celiac patients. Gastroenterology. (1996)
110:1368–78. doi: 10.1053/gast.1996.v110.pm8613040
44. Gajendran M, Loganathan P, Catinella AP, Hashash JG. A comprehensive
review and update on Crohn’s disease. Disease-a-Month. (2018) 64:20–
57. doi: 10.1016/j.disamonth.2017.07.001
45. Hüe S,Mention J-J, Monteiro RC, Zhang S, Cellier C, Schmitz J, et al. A direct
role for NKG2D/MICA interaction in villous atrophy during celiac disease.
Immunity. (2004) 21:367–77. doi: 10.1016/j.immuni.2004.06.018
46. Meresse B, Chen Z, Ciszewski C, Tretiakova M, Bhagat G, Krausz TN, et al.
Coordinated induction by IL15 of a TCR-independent NKG2D signaling
pathway converts CTL into lymphokine-activated killer cells in celiac disease.
Immunity. (2004) 21:357–66. doi: 10.1016/j.immuni.2004.06.020
47. Biagi F, Luinetti O, Campanella J, Klersy C, Zambelli C, Villanacci V, et al.
Intraepithelial lymphocytes in the villous tip: do they indicate potential
coeliac disease? J Clin Pathol. (2004) 57:835–9. doi: 10.1136/jcp.2003.013607
48. Collin P, Salmi TT, Hervonen K, Kaukinen K, Reunala T. Dermatitis
herpetiformis: a cutaneous manifestation of coeliac disease. AnnMed. (2017)
49:23–31. doi: 10.1080/07853890.2016.1222450
49. Myrsky E, Caja S, Simon-Vecsei Z, Korponay-Szabo IR, Nadalutti C,
Collighan R, et al. Celiac disease IgAmodulates vascular permeability in vitro
through the activity of transglutaminase 2 and RhoA. Cell Mol Life Sci. (2009)
66:3375–85. doi: 10.1007/s00018-009-0116-1
50. Marsh MN, Heal CJ. Evolutionary developments in interpreting the gluten-
induced mucosal celiac lesion: an archimedian heuristic. Nutrients. (2017)
9:213 doi: 10.3390/nu9030213
51. Leon F. Flow cytometry of intestinal intraepithelial lymphocytes
in celiac disease. J Immunol Methods. (2011) 363:177–
86. doi: 10.1016/j.jim.2010.09.002
52. Nijeboer P, van Gils T, Reijm M, Ooijevaar R, Lissenberg-Witte BI,
Bontkes HJ, et al. Gamma-Delta T Lymphocytes in the diagnostic
approach of coeliac disease. J Clin Gastroenterol. (2019) 53:e208–
e13. doi: 10.1097/MCG.0000000000001060
53. Fernández-Bañares F, Crespo L, Núñez C, López-Palacios N, Tristán E,
Vivas S, et al. Gamma delta+ intraepithelial lymphocytes and coeliac
lymphogram in a diagnostic approach to coeliac disease in patients with
seronegative villous atrophy. Aliment Pharmacol Ther. (2020) 51:699–
705. doi: 10.1111/apt.15663
54. Cooke WT, Holmes GKT. Coeliac Disease. New York, NY: Churchill
Livingstone (1984) .
55. Mohamed BM, Feighery C, Williams Y, Davies A, Kelleher D,
Volkov Y, et al. The use of cellomics to study enterocyte cytoskeletal
proteins in coeliac disease patients. Cent Eur J Biol. (2008)
3:258–67. doi: 10.2478/s11535-008-0029-2
56. Holmes G, Catassi C. Coeliac Disease (Fast Facts) 1st ed. Oxford: Health Pr.
(2000) .
57. Moss SF, Attia L, Scholes J V, Walters JR, Holt PR. Increased small intestinal
apoptosis in coeliac disease. Gut. (1996) 39:811–7. doi: 10.1136/gut.39.6.811
58. Das P, Gahlot GPS, Mehta R, Makharia A, Verma AK, Sreenivas V, et al.
Patients with mild enteropathy have apoptotic injury of enterocytes similar
to that in advanced enteropathy in celiac disease. Dig Liver Dis. (2016)
48:1290–5. doi: 10.1016/j.dld.2016.06.013
59. Ciccocioppo R, Di Sabatino A, Parroni R, Muzi P, D’Alò S, Ventura T, et al.
Increased enterocyte apoptosis and fas-fas ligand system in celiac disease. Am
J Clin Pathol. (2001) 115:494–503. doi: 10.1309/UV54-BHP3-A66B-0QUD
60. Adriaanse MPM, Tack GJ, Passos VL, Damoiseaux JGMC, Schreurs MWJ,
vanWijck K, et al. Serum I-FABP as marker for enterocyte damage in coeliac
disease and its relation to villous atrophy and circulating autoantibodies.
Aliment Pharmacol Ther. (2013) 37:482–90. doi: 10.1111/apt.12194
61. AdriaanseMPM, Leffler DA, Kelly CP, Schuppan D, Najarian RM, Goldsmith
JD, et al. Serum I-FABP detects gluten responsiveness in adult celiac disease
patients on a short-term gluten challenge. Am J Gastroenterol. (2016)
111:1014–22. doi: 10.1038/ajg.2016.162
62. Hoffmanová I, Sánchez D, Hábová V, Anděl M, Tučková L,
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